A New Paradigm

who we are
Use of mathematical modelling and simulation as a means to assist objective decision making and to enhance the reliability of R&D outcomes, while maximizing the value of animal & human data.

Our Story

MVT in Silico was founded on a simple but powerful belief that rigorous computational science can transform how we understand, prevent, and treat disease. Our belief is also that use of mathematical modelling through comptational methods will prevent redundant experimentation and simultaneously improve the reliability of R&D outcomes. At a time when biomedical research faces rising costs, increasing complexity, and urgent unmet clinical needs, we saw an opportunity to apply deep mathematical modeling, data science, and systems biology to make drug development smarter, faster, and more reliable.
What began as a small group of academic interdisciplinary scientists consisting of mathematicians (the founder) and biologists (Prof. Donald G. Welsh), and clinicians evolved into a focused mission to build transparent, reproducible in silico frameworks that bridge theory and therapeutic impact. The founder has extensive experience in mathematical modeling and simulation in the related fields of computational cardiology and fluid dynamics for blood flow phenomena, which primes us to apply these skills to the complex challenges of drug development. We are now a growing team of scientists, engineers, and glaring problems of drug development.
From early exploratory modeling projects to structured, validated computational pipelines, our growth has been driven by scientific discipline and an uncompromising commitment to quality. A natural way forward was to pursue the application of Pharmacometrics in addressing the pharma industry's pain points.
Along the way, we recognized that science needs to be both robust and transparent. See our (Science) page. Our story is shaped by the belief that models must be interpretable, verifiable, and grounded in biological reality to truly support decision-making in research and clinical development.
Our human centered computational solutions enhance reliability of R&D outcomes, while maximizing the value of animal & human data. We are now onboarding further clients for our specialist pharmacometrics services.